Share on LinkedInShare on LinkedIn

ARTICLE · 27 APRIL 2023

Another Win For Generics: Hatch-Waxman Defendants May Develop Non-Infringement Defenses Beyond Their Notice Letters

Crowell & Moring LLP
Crowell & Moring LLP
Contributor
Crowell & Moring LLP

Crowell & Moring LLP

Crowell & Moring’s Doha office is a full service legal practice that serves as the firm’s regional...

View firm profile
Explore more from Crowell & Moring LLP

Since the Supreme Court's 2017 sea change venue decision in TC Heartland v. Kraft Food Group Brands, the Northern District of West Virginia has seen an uptick in substantive Hatch-Waxman...

United StatesIntellectual Property

Since the Supreme Court's 2017 sea change venue decision in TC Heartland v. Kraft Food Group Brands, the Northern District of West Virginia has seen an uptick in substantive Hatch-Waxman litigation involving local pharmaceutical company, Viatris Inc. (formerly known as Mylan Pharmaceuticals). Viatris is frequently named as a defendant in Hatch-Waxman litigations, each of which is triggered by Viatris's service of a statutorily-required notice letter stating why the patents that allegedly cover the brand name drug are invalid and/or not infringed by a proposed generic drug. Hatch-Waxman litigants have battled over the requirements for these notice letters in other courts. In Bausch Health Ireland Ltd. et al. v. Mylan Pharms. Inc., the Northern District of West Virginia has now added to that body of law, adopting a holding consistent with other courts that a generic drug company is not foreclosed from asserting additional defenses in litigation even if those defenses

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from